PTCT PTC Therapeutics, Inc.
Healthcare$67.65-1.69%ClosedMarket Cap: $5.61B
As of 2026-05-26
Valuation
P/E (TTM)
8.44
PEG
0.03
P/B
-31.46
P/S
6.90
EV/EBITDA
-237.57
DCF Value
$-481.13
FCF Yield
-4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.8%
Operating Margin
-8.2%
Net Margin
-22.6%
ROE
99.8%
ROA
-6.5%
ROIC
-2.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $272.6M | 85.5% | $45.9M | $-2.8M | $— | — |
| Q4 null | $164.7M | 90.1% | $-81.6M | $-135.0M | $— | — |
| FY null | $1.73B | 95.9% | $856.5M | $682.6M | $— | — |
| Q3 null | $211.0M | 45.1% | $3.0M | $15.9M | $— | — |
| Q2 null | $178.9M | 93.6% | $-35.0M | $-64.8M | $— | — |
| Q1 null | $1.18B | 98.9% | $970.2M | $866.6M | $— | — |
| Q4 null | $213.2M | 92.4% | $-162.4M | $-65.9M | $— | — |
| FY null | $806.8M | 92.9% | $-302.6M | $-363.3M | $— | — |
| Q3 null | $196.8M | 94.5% | $-54.5M | $-106.7M | $— | — |
| Q2 null | $186.7M | 91.7% | $-40.2M | $-99.2M | $— | — |
| Q1 null | $210.1M | 93.0% | $-45.5M | $-91.6M | $— | — |
| Q4 2023 | $307.1M | 65.4% | $3.1M | $-155.8M | $-2.06 | — |